We describe immunoassays designed to quantitate phosphorylation of ALK, and their use in preclinical models of neuroblastoma, a pediatric malignancy in which gain‐of‐function ALK mutations predict a poor overall outcome to conventional treatment. The gene discussed is ALK; the disease is neuroblastoma.